合理设计的抗自纳米系统用于逆转瘤环境中的免疫抑制网络
Bo-Dou Zhang1, Xi Chen2, Jing-Yun Su1
1Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology (Ministry of Education), Department of Chemistry, Center for Synthetic and Systems Biology, Tsinghua University, Beijing, China.
Nanomedicine (London, England)
|May 22, 2025
概括
这项研究开发了一种新的纳米免疫疗法 (CQCP),通过抑制自和激活先天免疫来逆转胰腺癌的免疫抑制,显著改善小鼠的生存率.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 纳米技术 纳米技术
- 药物运输 药物运输 药物运输
背景情况:
- 胰腺管道腺癌 (PDAC) 具有免疫抑制性瘤微环境 (TME) 的特征.
- 逆转这种免疫抑制对于有效的癌症免疫疗法至关重要.
- 目前的治疗方法往往难以克服TME的抗药性.
研究的目的:
- 设计一个pH响应的纳米系统 (CQCP),同时提供一种自抑制剂 (氨酸) 和一种STING激动剂 (循环 diguanylate).
- 评估CQCP在逆转PDAC免疫抑制和增强抗瘤免疫力的有效性.
- 在临床前模型中评估CQCP对抗原呈现,免疫细胞激活和整体存活率的影响.
主要方法:
- 开发CQCP纳米系统使用pH响应的聚合物PC7A.
- 在体外和体内对自抑制,MHC-I表达和树突细胞激活的评估.
- 量化瘤透淋巴细胞 (CD8+ T细胞) 和全身免疫反应.
- 用CQCP治疗的PDAC携带小鼠的生存率的评估.
主要成果:
- CQCP显著增强了PDAC细胞上的MHC-I表达 (增加了2.1倍).
- 激活的树突细胞 (CD86+/CD40+) 在TME中增加了3.5倍.
- 瘤透的CD8+ T细胞增加了42.6%,观察到全身免疫激活.
- 在携带瘤的小鼠中,CQCP实现了86%的存活率,超过单一疗法.
结论:
- 该CQCP纳米系统通过恢复抗原呈现和激活先天免疫力来协同逆转PDAC免疫抑制.
- 这种双重向的纳米免疫疗法显示出强大的抗瘤疗效.
- CQCP代表了胰腺管道腺癌的有前途的治疗策略.
更多相关视频
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
5.9K
09:10siRNA Electroporation to Modulate Autophagy in Herpes Simplex Virus Type 1-Infected Monocyte-Derived Dendritic Cells
Published on: October 28, 2019
7.2K
相关概念视频
Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
